Gencurix Inc

229000

Company Profile

  • Business description

    Gencurix Inc develops diagnosis treatment kits. The company focuses on developing molecular diagnostic tests based on core technologies of liquid biopsy and biomarker discovery. It offers products including GenesWell BCT, a breast cancer test, GenesWell ddEGFR Mutation Test, Droplex, eDX, Geno CTC, and others.

  • Contact

    243 Digital-ro
    15th floor, Jiha City
    Guro-gu
    Seoul
    KOR

    T: +82 7074329481

    https://www.gencurix.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Diagnostics & Research

    Fiscal Year End

    31 December 2025

    Employees

    69

Stocks News & Analysis

stocks

Strong finish to the year for overvalued ASX share

A great fiscal 2025 but investors are ahead of themselves.
stocks

Our three most overvalued ASX shares

These three companies are trading at a significant premium to our fair value.
stocks

What does big US court decision mean for Google’s parent company Alphabet?

Alphabet shares popped 7% after the ruling on September 2 and have now rallied by around 50% since April.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,062.5058.00-0.64%
CAC 407,734.8460.060.78%
DAX 4023,807.13210.150.89%
Dow JONES (US)45,514.95114.090.25%
FTSE 1009,221.4413.230.14%
HKSE25,787.09153.180.60%
NASDAQ21,798.7098.310.45%
Nikkei 22543,548.6395.18-0.22%
NZX 50 Index13,253.7327.41-0.21%
S&P 5006,495.1513.650.21%
S&P/ASX 2008,784.7056.20-0.64%
SSE Composite Index3,800.5626.28-0.69%

Market Movers